|
(SC2) THE CHALLENGE OF THE
BLOOD-BRAIN BARRIER – A MEDICINAL CHEMISTRY PERSPECTIVE
10:15 The In’s and Out’s of
Blood-brain Transport: Blood-brain Barrier Physiology and
Transport Methodologies
Claude Dagenais, B.Pharm., Ph.D. Senior Scientist,
Neuroscience Department, Amgen Inc.
11:00 The Challenge of the
Blood-Brain Barrier
Douglas K. Spracklin, Ph.D., Director, Biotransformation
& Enzymology, Pfizer Inc.
11:40 Coffee Break
12:00pm Application of
Pharmacokinetic/Pharmacodynamic Modeling to Centrally
Targeted Agents
Ellen Q. Wang, Ph.D., Senior Principal Scientist,
Pharmacokinetics, Dynamics and Metabolism, Pfizer Global
Research and Development
12:30 Blood-brain Barrier Models
Romeo Cecchelli, Ph.D., Vice President, University of Artois;
Head, BBB
Laboratory; Scientific Advisor, Cellial Technologies
1:00 Q&A
1:15 End of Course
(SC3) ADMET CASE STUDIES FROM A
MEDICINAL CHEMISTRY PERSPECTIVE
10:15 Introduction & Welcome
Philip S. Burton, Ph.D., Chief Executive & Scientific
Officer, ADMETRx, Inc.
10:20 In Vitro ADME Assays:
Strategic Application to Drug Discovery
Dhiren R. Thakker, Ph.D., Ferguson Distinguished Professor
and Associate Dean, Research and Graduate Education, School
of Pharmacy, UNC-Chapel Hill
-
Why ADME assays in drug
discovery?
-
Strategic use of in vitro
ADME assays and preclinical pharmacokinetic studies in
drug discovery
-
Current status of ADME in drug
discovery and future developments
11:00 Solubility, Data Integration,
in Vitro/in Vivo Correlations
Philip S. Burton, Ph.D., Chief Executive & Scientific
Officer, ADMETRx, Inc.
Solubility evaluation models
Extrapolating in vitro
data to in vivo performance
11:40 Coffee Break
12:00pm In Vitro Toxicity
Assays That Have in Vivo Relevance
James McKim, Ph.D., DABT, President & Chief Scientific
Officer, CeeTox, Inc.
12:40 Case Study: Impact of
Structure and Physchem Properties on Oral Delivery of
Antivirals
Gail L Strong, Ph.D., Director, Pharmaceutical Sciences,
Theravance, Inc.
1:00 Q&A
1:15 End of Course |
|
(SC8) MODELS FOR EVALUATING
DRUG-DRUG INTERACTION POTENTIAL IN PRECLINICAL DEVELOPMENT
2:30 From Benchtop to
Regulatory Guidance: Effective Strategies to Identify
Drug-Drug Interaction (DDI) Liability
Joseph Ware, Ph.D., Senior Scientist, Late Stage PK/PD,
Genentech, Inc.
The ability to move a test compound rapidly into the
clinic and to plan effectively for its clinical development
will in part depend on effective preclinical assessments of
the interactions of drug candidates with drug metabolizing
enzymes and drug transporters. The following presentation
will highlight:
-
An overview of clinically
significant cytochrome P450-mediated DDIs
-
An introduction to an
integrated-approach of transporter biology within drug
discovery and development
-
What similarities and
differences exist between strategies to identify and
context CYP-mediated DDIs versus transporter-mediated
DDIs?
3:10 In vitro Models of CYP
Inhibition and Induction
James McKim, Ph.D., DABT, President & Chief Scientific
Officer, CeeTox, Inc.
-
Methodology
-
In vitro/in vivo
correlations
3:50 Coffee Break
4:10 In Vitro Drug
Transporter Models
Philip S. Burton, Ph.D., Chief Executive & Scientific
Officer, ADMETRx, Inc.
4:50 Q&A
5:00 End of Course
* Separate Registration Required |
Harry Glorikian, Managing Partner, Scientia Advisors
Clayton M. Christensen, DBA, Robert and Jane Cizik Professor of Business Administration, Harvard Business School
